

OIE Reference Laboratory Reports Activities

Activities in 2019

This report has been submitted : 2020-01-14 11:41:03

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Infectious bovine rhinotracheitis/infectious pustular vulvovaginitis
Address of laboratory:	Südufer 10 D-17493 Greifswald Insel Riems GERMANY
Tel.:	+49 38351 7 1223
Fax:	+49 38351 7 1275
E-mail address:	martin.beer@fli.de
Website:	www.fli.de
Name (including Title) of Head of Laboratory (Responsible Official):	Prof. Dr. Martin Beer
Name (including Title and Position) of OIE Reference Expert:	Prof Dr. Martin Beer (head of laboratory) Dr. Patricia König (deputy head of laboratory; patricia.koenig@fli.de)
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
BHV-1 whole virus ELISA	yes	284	136
BHV-1 gB blocking ELISA	yes	1250	183
BHV-1 gE blocking ELISA	yes	757	176
BHV-1 bulk milk ELISA	yes	120	0
BHV-2 whole virus ELISA	no	50	66
Bo/BuHV-1 differentiating ELISA	no	49	0
serum neutralisation test	yes	38	99
Direct diagnostic tests		Nationally	Internationally
virus isolation in cell culture	yes	4	0
IFA	yes	4	0
PCR	yes	39	0

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
milk samples	bulk milk antibody ELISA	0/30	31x1ml	127x1ml	2	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
serum samples	antibody ELISA, SNT	0/50	29x1ml	205x1ml	10	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
meat juice samples	antibody ELISA	2/2	4x1ml	0	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
DNA	PCR	0/15	4	0	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
virus stocks	virus isolation, IFA, SNT, PCR	0/10	2	10	3	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

Yes

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

Name of the new test or diagnostic method or vaccine developed	Description and References (Publication, website, etc.)
Validation of detection of BHV-1 antibodies in meat juice samples of beef cattle: further validation (extended assay spectrum, washing procedure)	<p>nationally published: Lab-Loeffler 2/2017 No 15 https://www.openagrar.de/servlets/MCRFileNodeServlet/openagrar_derivate_00008231/LabLOEFFLER_15_2017_Web.pdf</p>

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
ITALY	April	2	0
ITALY	May	3	0
ITALY	May	32	0
ITALY	August	6	0
ITALY	August	3	0
ITALY	November	3	0
SPAIN	December	19	0

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
FINLAND	virus isolation in cell culture	Email and material transfer
ETHIOPIA	BHV-1 genome detection in bovine semen	Email
SPAIN	test validation	Email
IRELAND	neutralisation test	Email and material transfer
SPAIN	AI bull testing	Email
ECUADOR	eradication programme	Email
SWITZERLAND	test development	Email, audioconference, testing
CANADA	test validation	Email

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Detection of gE antibodies in bulk milk samples	2017-2020	Validation of a reliable test System for the detection of gE antibodies in concentrated milk samples	TGD e.V. Poing, Germany In3Diagnostic, Italy	ITALY

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Institute of Epidemiology at FLI is hosting the disease notification system TSN

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
FLI (Institute of Epidemiology) and the Swiss Federal Food Safety and Veterinary Office (BLV) are distributing the "Radar Bulletin". The Radar Bulletin compiles and evaluates information on the global situation and on the spread of the most important animal diseases which are relevant for Germany and Switzerland. FLI (Institute of Epidemiology) collects data and presents the annually reporting of the number of examinations, diagnostic tests carried out and outbreak statistics to the EU

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 4

b) International conferences: 3

IABS(International Alliance for Biological Standardization)

Workshop on Diagnostics in the Veterinary Field

The Role in Health Surveillance and Disease Identification, May 15-17, 2019, Wiesbaden, Germany

DIVA in DNA: Pseudorabies and IBR

König P., Müller T., and Beer M.

Italian Association of Veterinary Laboratory Diagnosticians, Matera, Italy, October 23-25th 2019 CROSS REACTIVITY ANTIBODY RESPONSE BETWEEN BOVINE ALPHAHERPESVIRUS 2 (BOHV-2) AND BOVINE ALPHAHERPESVIRUS 1 (BOHV-1) IN A CALF FROM A PERFORMACE TEST STATION IN CENTRAL ITALY

Righi C., Koenig P., Scorcelletti S., Vagniluca A., Casciari C., Pellegrini C., Giammarioli M., Petrini S.

c) National conferences: 1
 9. Riemser Diagnostiktage
 27.-29.11.2019 Greifswald, Germany
 BHV-1 - A never ending story?
 Beer M., König P., Probst C., Conraths FJ.

d) Other:
 (Provide website address or link to appropriate information) 2
www.fli.de
 Tiergesundheitsjahresbericht 2019/Hrsg. Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025	AKS_Eintrag_2007.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
flexible accreditation: ELISA (marker and conventional) on blood and milk samples, SNT	ILAC MRA
flexible accreditation: VI, IFA, NA extraction, PCR	ILAC MRA
flexible accreditation: RFLP	ILAC MRA

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
RIngtrial	Comparison of diagnostics	APHA, Weybridge, UK

ToR 11: To organise inter-laboratory proficiency testing with laboratories other

than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons ¹	No. participating laboratories	Region(s) of participating OIE Member Countries
Participating: Herpesvirus detection	11	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East
Organisation: -antibody blood -antibody detection milk -virus detection (VI, PCR)	approx. 50	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
European Expert Group to discuss Delegated Acts on IBR: Supporting documents to discuss a delegated act on surveillance, eradication programmes and disease free status for terrestrial animals - AHL, Brussels; public consultation	remote (Email, phone)	harmonisation and standardisation of definitions, diagnostic methods and schemes within the European Union in accordance to OIE standards

25. Additional comments regarding your report:

The OIE laboratory is in charge with test licensing (2 Kits) and batch release in Germany (35 batches in 2019).